Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab). (2020). Archives of Clinical and Medical Case Reports, 4(1), 8-14. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22266